Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2021 Earnings Presentation
32 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2022
Slide 1: FY2021 Results Update
x FY2021 Results Update
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
LIST OF FIGURES Market Overview and Growth Corporate Overview 04 16 Financial Update 28 Strategy Company Highlight 05 Indonesia Economy Outlook 17 Gross Profit and Net Income 29 Global Trend in Diagnostic Lab Company History 06 18 COGS and OPEX 30 Market Investment Highlight 07 Growth Strategy 19 Fi
Slide 4: Corporate Overview
1 CORPORATE OVERVIEW 4
Slide 5: Company Highlight
• More than 49 years IDR 2.65 Trillion experience in Clinical Lab Industry since 1973 FY2021 Revenue (+41.6% yoy) • Has the most recognized Brand in Indonesia >3.6 Million • Largest private FY2021 Visit (+17.7% yoy) independent clinical lab chain by size of network and revenue, with 39.5% market sha
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing The first private lab in Indonesia Established professional Established that using fully automated Cobas Received SMK3 management team Prodia ChildLab 6800 for RT-PCR COVID-19 testing accreditation and Launched Partnerships OHSAS 2015 La
Slide 7: Investment Highlight
2 INVESTMENT HIGHLIGHT 7
Slide 8: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2019 & 2020) (Billion IDR) 3YRS CAGR 7.4% 39.2% 39.5% 4,874 3YRS CAGR 4,222 4,551 8.2% 26.9% 2019 27.8% 2020 1,600 1,744 1,873 33.9% 32.7% 2018 2019
Slide 9: Strong Operational Track Record
Strong Operational Track Record VISITS REVENUE CAGR CAGR 7.7% 14.3% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 6.1% CAGR 34.4% 9 2016 2
Slide 10: Comprehensive Service Offering with Multiple Customer Segments
Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin
Slide 11: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Significant Surabaya, Medan, Makassar Economies of Scale Achieved “Hub and spoke” model offers scalable platform reducing Centralized information Prodia Clinical Labs, Prodia Referral with integrated IT turnaround time and cost Hospit
Slide 12: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin
Slide 13: Prodia Sustainable Action Plan
Prodia Sustainable Action Plan Prodia Sustainable Action Plan is an initiative and effort made by Prodia in order to achieve sustainable business growth so as to create added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment.
Slide 14: Experienced Senior Leadership and Management Team
Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 30 Experience 30 Experience Andi Gunawan Endang Kemal Imam Keri
Slide 15: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 16: Market Overview & Growth Strategy
3 MARKET OVERVIEW & GROWTH STRATEGY 16
Slide 17: Indonesia Economic Outlook
Indonesia Economic Outlook 4.8% – 5.9% Indonesia’s GDP Growth Projection for 2022 Indonesia’s economic recovery and improvement in 2022 will GDP Growth Projection 2022 be supported by the Indonesia World stability to control Indonesia’s Govt’ 5.2% N/A COVID-19 pandemic, World Bank 5.2% 4.1% response
Slide 18: Global Trend in Diagnostic Lab Market
Global Trend in Diagnostic Lab Market 1 2 3 4 Creating Digital Strategic Customer Centric Development of Ecosystem Partnership and Model testing technology Collaboration and AI Healthcare Platform B2B Business Expansion Digital Customer Journey Preventive Genomics Electronic Health Record Market Con
Slide 19: Company's Growth Strategy
Company’s Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance int
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: Our Response to Business Landscape
Our Response to Business Landscape • Wellness Package • Genomic Tests • Upgrade Prodia apps • ProdiaLink for ER • Ethos – HS platform • Prodia in Your Car Lab Market: Digital Service Development Product and Lab Testing Innovation New Players Coming • License Upgrade • Added more HS • Adjusted Facili
Slide 22: Business Update
4 BUSINESS UPDATE 22
Slide 23: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Facilities Product Innovation • Safety, Quality & Cleanliness of Our Lab/Facilities/Staffs • Complete Testing from Routine to Esoteric Test, Genomics Testing • Prodia Mobile • Testing package
Slide 24: Customer Centric Model: New Innovation & Enhancement
Customer Centric Model Prodia in your Car New Innovation & Enhancement Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners ProdiaLink • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 24
Slide 25: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs Prodia Mobile apps provides online registration/booking, online payment, online results, and chat with doctors > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3.3.0 – Updated in Sep 2021 25
Slide 26: Outlet Development
Outlet Development 2016-2021 Outlet Development 2022 Outlet Development Target 1-2 20 259 283 292 287 267 259 Clinical Labs POC Outlets 5 7 4** 2 4** 4** 11 14 14 12 9 9 Total Outlet 1-2 1 130 128 122 103 95 118 Specialty Clinics Hospital Labs Specialty Clinic Hospital Lab 129 136 143 147* 148* 148*
Slide 27: FY2021 Revenue
FY2021 Revenue Revenue (Audited) Quarterly Revenue (Unaudited) in IDR Billion in IDR Billion 2021 2020 2019 • Revenue grew by FY16-FY21 CAGR +14.3% +41.6% yoy, driven 2018 2017 2016 by all customer FY20-FY21 segment especially growth: +41.6% 3Q21, walk in and doctor 4Q21, 752.3 referrals. 2,652.3 1Q
Slide 28: Financial Update
5 FINANCIAL UPDATE 28
Slide 29: FY2021 Gross Profit & Net Income (Audited)
FY2021 Gross Profit & Net Income (Audited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY16-FY21 CAGR +15.5% FY16-FY21 CAGR +47.8% FY20-FY21 FY20-FY21 growth +56.1% growth +131.3% 1,632.7 621.6 942.8 1,041.0 1,046.2 793.4 853.5 268.7 23.4% 61.6% 175.5 210.3 58.9% 59.7% 150.8 58.4% 58.2
Slide 30: FY2021 COGS & OPEX (Audited)
FY2021 COGS & OPEX (Audited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY21 CAGR +12.5% FY16-FY21 CAGR +5.4% FY20-FY21 growth FY20-FY21 growth +23.3% +17.8% ,200 1,020 50.0% 1,000 878 70.0% 827 770 746 42 ,000 827.2 800 676 713 50 703.3 146 46 30 60.0% 800 656.9 45.0% 39 41 565.0 612.5 125 60
Slide 31: FY2021 Financial Summary (Audited)
FY2021 Financial Summary (Audited) (in IDR Bn) FY2021 FY2020 Change (in IDR Bn) FY2021 FY2020 Change Revenue 2,652.3 1,873.4 +41.6% Total Asset 2,718.6 2,232.0 +21.8% Gross Profit 1,632.7 1,046.2 +56.1% Total Equity 2,252.3 1,788.3 +25.9% EBIT 756.6 301.8 +150.7% EBT 786.6 339.1 +132.0% Net Income 6
Slide 32: Thank You!
THANK YOU! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id 32